ANAB

NASDAQ 已收盘

AnaptysBio

47.40 USD
▲+0.34+0.72%
盘后 47.68 0.00%
2026-11-19
市值
$1.39B
市盈率
7.24
EPS
6.44
股息率
—
52 周区间
33.10 – 73.30
成交量
507.01K
Beta
0.37
目标价
87.25
52W 低 33.1052W 高 73.30
价格走势

公司简介

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclus...